This Article Full Text Full Text (PDF) CME: Take the course for this article: Rhabdomyosarcoma: New Windows of Opportunity eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Breitfeld, P. P. Articles by Meyer, W. H. Search for Related Content PubMed PubMed Citation Articles by Breitfeld, P. P. Articles by Meyer, W. H.

Rhabdomyosarcoma: New Windows of Opportunity

^a Duke University Medical Center, Durham, North Carolina, USA; ^b University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

Correspondence: William H. Meyer, M.D., University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Telephone: 405-271-5311; Fax: 405-271-3756; e-mail: william-meyer{at}ouhsc.edu

Rhabdomyosarcoma is a highly malignant, small blue cell tumor characterized by muscle differentiation. With modern treatment, more than 70% of children and adolescents with this disease are cured. Adequate biopsy to obtain sufficient tissue for accurate diagnosis and molecular characterization is critical. Patients must be assessed for tumor extent; the Intergroup Rhabdomyosarcoma Study (IRS) clinical group and Staging system is universally applied in North America. Multidisciplinary therapy is necessary to maximize cure rates. Local control relies on complete surgical excision when possible; those whose tumors are not completely excised and those with alveolar histology tumors require local irradiation to maximize local control. In North America, vincristine (Oncovin^®; Eli Lilly and Company, Indianapolis, http://www.lilly.com), dactinomycin (Cosmegen^®; Merck & Co., Inc., Whitehouse Station, NJ, http://www.merck.com), and cyclophosphamide are the standard chemotherapy agents. The IRS has used therapeutic window studies to confirm the predictive nature of preclinical xenograft models and to identify several new single agents and combinations of agents with activity in high-risk patient groups. Despite these efforts, the outcome for these high-risk patients remains poor. The next generation of Children’s Oncology Group studies will evaluate the efficacy of topoisomerase-I inhibitors and dose-compression therapy approaches. New advances in molecular characterization of tumors, including gene-expression analysis, may identify new therapeutic targets that can be exploited by expanded preclinical drug discovery efforts, and hold the promise of revolutionizing risk-based therapies.

Key Words. Rhabdomyosarcoma • Child • Therapy • Radiotherpy • Sarcoma • Soft-tissue neoplasms • Antineoplastic agents • Human

This article has been cited by other articles:

				F. Diomedi-Camassei, H. P. McDowell, M. A. De Ioris, S. Uccini, P. Altavista, G. Raschella, R. Vitali, O. Mannarino, L. De Sio, D. A. Cozzi, et al. Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma Clin. Cancer Res., July 1, 2008; 14(13): 4119 - 4127. [Abstract] [Full Text] [PDF]

				D. C. Phillips, S. Martin, B. T. Doyle, and J. A. Houghton Sphingosine-Induced Apoptosis in Rhabdomyosarcoma Cell Lines Is Dependent on Pre-Mitochondrial Bax Activation and Post-Mitochondrial Caspases Cancer Res., January 15, 2007; 67(2): 756 - 764. [Abstract] [Full Text] [PDF]